{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:28:47Z","timestamp":1787506127989,"version":"build-2736575974"},"reference-count":247,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharmr.2026.100135","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:03:18Z","timestamp":1775840598000},"page":"100135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thrombin generation and the pharmacodynamics of parenteral anticoagulants"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-7912","authenticated-orcid":false,"given":"Joseph R.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-2674","authenticated-orcid":false,"given":"Cheryl L.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-9417","authenticated-orcid":false,"given":"Micha\u00ebl","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-6099","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo ten","family":"Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-3064","authenticated-orcid":false,"given":"Paul Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.pharmr.2026.100135_bib1","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1016\/S0021-9258(18)42309-5","article-title":"Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement","volume":"267","author":"Olson","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/jmbi.1998.2083","article-title":"Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin","volume":"283","author":"Skinner","year":"1998","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood-2005-02-0547","article-title":"The heparin-binding site of antithrombin is crucial for antiangiogenic activity","volume":"106","author":"Zhang","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beha.2004.03.004","article-title":"Fondaparinux: a new synthetic and selective inhibitor of Factor Xa","volume":"17","author":"Bauer","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib5","first-page":"819","article-title":"The direct thrombin inhibitor hirudin","volume":"99","author":"Greinacher","year":"2008","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib6","first-page":"830","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"issue":"3 Suppl","key":"10.1016\/j.pharmr.2026.100135_bib7","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100135_bib8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1161\/01.CIR.98.15.1575","article-title":"Low-molecular-weight heparin : a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina","volume":"98","author":"Hirsh","year":"1998","journal-title":"Circulation"},{"issue":"2 Suppl","key":"10.1016\/j.pharmr.2026.100135_bib9","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of heparin and related drugs: an update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib11","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1055\/a-2359-0987","article-title":"Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points","volume":"8","author":"Gouin-Thibault","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.pharmr.2026.100135_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221145010","article-title":"Fondaparinux sodium: recent advances in the management of thrombosis","volume":"28","author":"Bauersachs","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/ATVBAHA.124.321650","article-title":"Andexanet Alfa-associated heparin resistance in cardiac surgery: mechanism and in vitro perspectives","volume":"45","author":"Chabata","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jtha.2025.02.024","article-title":"Emergent cardiac surgery, andexanet alfa-induced heparin resistance, and prothrombotic effects: coagulation chaos?","volume":"23","author":"Shaw","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100135_bib16","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/hematology.2024000566","article-title":"Practical guide to the diagnosis and management of heparin-induced thrombocytopenia","volume":"2024","author":"May","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100135_bib18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"issue":"6 Suppl","key":"10.1016\/j.pharmr.2026.100135_bib19","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0036-1597297","article-title":"Laboratory monitoring of parenteral direct thrombin inhibitors","volume":"43","author":"Van Cott","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib21","first-page":"747","article-title":"Phenotyping the clotting system","volume":"84","author":"Hemker","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/jcp.6.1.3","article-title":"A thrombin generation test; the application in haemophilia and thrombocytopenia","volume":"6","author":"MACFARLANE","year":"1953","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038782","article-title":"Thrombosis, translational medicine, and biomarker research: moving the needle","volume":"14","author":"Shaw","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib25","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2007.06785.x","article-title":"Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study","volume":"139","author":"Dargaud","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib27","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"Kintigh","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100135_bib29","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2005.05612.x","article-title":"The measurement and application of thrombin generation","volume":"130","author":"Baglin","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jth.15589","article-title":"Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa","volume":"20","author":"Maag","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","article-title":"Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","volume":"21","author":"Shaw","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100135_bib34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"Hron","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100135_bib36","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pharmr.2026.100135_bib37","first-page":"a25346123","article-title":"Risk of first venous thrombosis by comparing different thrombin generation assay conditions: results from the MEGA case-control study","volume":"9","author":"Winckers","year":"2025","journal-title":"TH Open"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1749-8090-8-154","article-title":"Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article","volume":"8","author":"Bosch","year":"2013","journal-title":"J Cardiothorac Surg"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1538-7836.2010.04146.x","article-title":"Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding","volume":"9","author":"Coakley","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176967","article-title":"Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing","volume":"12","author":"Bloemen","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib42","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/jcm9072018","article-title":"Delayed thrombin generation is associated with minor bleedings in venous thromboembolism patients on Rivaroxaban: usefulness of calibrated automated thrombography","volume":"9","author":"Zalewski","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIRCULATIONAHA.113.003191","article-title":"Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein","volume":"128","author":"Schuijt","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib44","first-page":"283","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib45","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of Rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of Rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib46","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1055\/s-0038-1657772","article-title":"Betrixaban: impact on routine and specific coagulation assays-A practical laboratory guide","volume":"118","author":"Siriez","year":"2018","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1160\/th15-05-0415","article-title":"Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide","volume":"115","author":"Douxfils","year":"2016","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100135_bib48","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/j.1538-7836.2007.02753.x","article-title":"Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants","volume":"5","author":"Samama","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MBC.0b013e32835e4219","article-title":"Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro","volume":"24","author":"Xu","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib50","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","article-title":"In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux","volume":"129","author":"Samama","year":"2012","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0037-1616110","article-title":"Platelets and phospholipids in tissue factor-initiated thrombin generation","volume":"86","author":"Butenas","year":"2001","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib52","first-page":"547","article-title":"Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability","volume":"88","author":"Chantarangkul","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.95.1.118","article-title":"Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate","volume":"95","author":"Cosmi","year":"1997","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib55","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/ijlh.13356","article-title":"Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing","volume":"43","author":"Evrard","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/rth2.12497","article-title":"Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram","volume":"5","author":"Helin","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.thromres.2008.03.018","article-title":"Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment","volume":"123","author":"Brodin","year":"2009","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MBC.0000000000000678","article-title":"Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed","volume":"29","author":"Rigano","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2011.08.027","article-title":"The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients","volume":"130","author":"Lawrie","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib60","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","article-title":"Effect of factor XI inhibition on tumor cell-induced coagulation activation","volume":"22","author":"M\u00e4der","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtha.2022.10.020","article-title":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro","volume":"21","author":"Guan","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100135_bib67","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100135_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027852","article-title":"Anticoagulants and the propagation phase of thrombin generation","volume":"6","author":"Orfeo","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation","volume":"23","author":"Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","article-title":"Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?","volume":"35","author":"Dale","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100135_bib71","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib72","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100135_bib73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib74","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100135_bib75","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100135_bib76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib77","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension","volume":"18","author":"Bunclark","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100135_bib79","first-page":"S250","article-title":"Anticoagulation post-pulmonary endarterectomy: a retrospective cohort study","volume":"39","author":"Raslan","year":"2023","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmr.2026.100135_bib80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2020.04.020","article-title":"VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis","volume":"190","author":"Sivaraja","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2026.100135_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620954913","article-title":"Comparative anticoagulant and thrombin generation inhibitory profile of heparin, sulodexide and its components","volume":"26","author":"Siddiqui","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib82","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620960820","article-title":"Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version","volume":"26","author":"Qneibi","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib83","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/rth2.12120","article-title":"Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots","volume":"2","author":"Salta","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib84","first-page":"111","article-title":"Exploring potential anticoagulant drug formulations using thrombin generation test","volume":"5","author":"Zavyalova","year":"2016","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.pharmr.2026.100135_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2015.12.007","article-title":"In vitro and in vivo characterization of a reversible synthetic heparin analog","volume":"138","author":"Whelihan","year":"2016","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116835","article-title":"Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib87","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.thromres.2015.06.034","article-title":"Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin","volume":"136","author":"Furugohri","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib88","first-page":"378","article-title":"Thrombin generation increasing with age and decreasing with use of heparin indicated by calibrated automated thrombogram conducted in Chinese","volume":"27","author":"Wu","year":"2014","journal-title":"Biomed Environ Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib89","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/MBC.0000000000000178","article-title":"Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation","volume":"25","author":"Levy","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib90","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1076029612463427","article-title":"Comparative studies on branded enoxaparin and a US generic version of enoxaparin","volume":"19","author":"Walenga","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3324\/haematol.2012.073601","article-title":"Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation","volume":"98","author":"Bloemen","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib92","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ijlh.13836","article-title":"Monitoring of heparin therapy beyond the anti-Xa activity assay: evaluation of a thrombin generation assay","volume":"44","author":"Vermeiren","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100135_bib93","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1538-7836.2012.04892.x","article-title":"Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism","volume":"10","author":"Buyue","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2010.10.017","article-title":"Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux","volume":"127","author":"Szlam","year":"2011","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib95","first-page":"1076","article-title":"Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system","volume":"106","author":"Furugohri","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib96","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MBC.0b013e328344f7d0","article-title":"Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation","volume":"22","author":"Ben-Hadj-Khalifa","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib97","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.phrs.2008.12.003","article-title":"Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?","volume":"59","author":"Robert","year":"2009","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.trsl.2008.12.004","article-title":"Regulation of thrombin generation by TFPI in plasma without and with heparin","volume":"153","author":"Brodin","year":"2009","journal-title":"Transl Res"},{"issue":"S 01","key":"10.1016\/j.pharmr.2026.100135_bib99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0028-1086087","article-title":"Effect of argatroban versus Recombinant Hirudin on Tissue-Factor-Mediated thrombin Generation: an in vitro Study","volume":"34","author":"Samama","year":"2008","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/FTD.0b013e31818b0d71","article-title":"Differential effects of factor IIa inhibitors on the endogenous thrombin potential","volume":"30","author":"Beilfuss","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib101","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/01.ane.0000278868.23814.3b","article-title":"Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin","volume":"105","author":"Tanaka","year":"2007","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib102","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2006.03.004","article-title":"The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT","volume":"119","author":"Cimenti","year":"2007","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib103","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MBC.0b013e32814fcdb8","article-title":"Influence of bivalirudin on tissue factor-triggered coagulation","volume":"18","author":"Butenas","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib104","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mbc.0000214708.73374.ce","article-title":"The effect of different anticoagulants on thrombin generation","volume":"17","author":"Petros","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib105","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2006.01830.x","article-title":"Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro","volume":"4","author":"Gould","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib106","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1213\/01.ANE.0000134685.75813.EB","article-title":"The effects of argatroban on thrombin generation and hemostatic activation in vitro","volume":"99","author":"Tanaka","year":"2004","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib107","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis","volume":"2","author":"Ieko","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00001721-200403000-00006","article-title":"Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma","volume":"15","author":"Gerotziafas","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib109","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001721-200309000-00007","article-title":"Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor","volume":"14","author":"Lisman","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"52","key":"10.1016\/j.pharmr.2026.100135_bib110","doi-asserted-by":"crossref","first-page":"50439","DOI":"10.1074\/jbc.M208222200","article-title":"Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban. I. Effects on thrombin generation","volume":"277","author":"Nagashima","year":"2002","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib111","first-page":"1012","article-title":"Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition","volume":"88","author":"Koestenberger","year":"2002","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib112","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00001721-200007000-00005","article-title":"Effects of the glycoprotein IIb\/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro","volume":"11","author":"Koestenberger","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0037-1614486","article-title":"Contribution of erythrocytes to thrombin generation in whole blood","volume":"81","author":"Peyrou","year":"1999","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib114","first-page":"1687","article-title":"The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants","volume":"82","author":"Mohri","year":"1999","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib115","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1055\/s-0038-1657717","article-title":"Inhibition of thrombin generation in plasma by inhibitors of factor Xa","volume":"78","author":"Prasa","year":"1997","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib116","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1055\/s-0038-1655996","article-title":"The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation","volume":"77","author":"Prasa","year":"1997","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00001721-199601000-00003","article-title":"Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods","volume":"7","author":"Houbouyan","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1055\/s-0038-1650629","article-title":"Human umbilical vein smooth muscle cells as a model to study thrombin generation and function: effect of thrombin inhibitors","volume":"76","author":"Catalioto","year":"1996","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib119","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00001721-199509000-00009","article-title":"Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46\u20136240), recombinant hirudin and heparin in human plasma","volume":"6","author":"Gast","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0038-1648815","article-title":"Measurement of thrombin generation in whole blood--the effect of heparin and aspirin","volume":"72","author":"Kessels","year":"1994","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib121","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1647337","article-title":"The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma","volume":"64","author":"Lindhout","year":"1990","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0038-1646521","article-title":"The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin","volume":"61","author":"B\u00e9guin","year":"1989","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib123","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0049-3848(86)90022-8","article-title":"Effects of EACA on thrombin generation as measured by the chromagen S2238","volume":"44","author":"Sloan","year":"1986","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2010.07.024","article-title":"Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography","volume":"127","author":"Hacquard","year":"2011","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib125","first-page":"166","article-title":"Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects","volume":"108","author":"Zahir","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2010.535512","article-title":"Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity","volume":"27","author":"Altman","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1160\/TH08-10-0653","article-title":"Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin","volume":"102","author":"Gerotziafas","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2009.05.022","article-title":"Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to enoxaparin (STACKENOX) study","volume":"158","author":"Drouet","year":"2009","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2004.02.009","article-title":"The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma","volume":"113","author":"Bostr\u00f6m","year":"2004","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib130","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1538-7836.2004.00798.x","article-title":"Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time","volume":"2","author":"al Dieri","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib131","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00001721-200307000-00005","article-title":"Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects","volume":"14","author":"Bostr\u00f6m","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib132","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0038-1642435","article-title":"Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers","volume":"71","author":"Bendetowicz","year":"1994","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib133","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1055\/s-0038-1648946","article-title":"The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers","volume":"72","author":"Bendetowicz","year":"1994","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib134","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2010.03917.x","article-title":"Anticoagulation by factor Xa inhibitors","volume":"8","author":"Orfeo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib135","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619895120","article-title":"Assay-based differentiation in the neutralization profile of unfractionated heparin, enoxaparin, and fondaparinux by andexanet Alfa","volume":"26","author":"Siddiqui","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib136","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bja.2024.02.027","article-title":"Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro","volume":"132","author":"Mishima","year":"2024","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib137","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1160\/TH15-12-0927","article-title":"Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay","volume":"116","author":"Bourti","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib138","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241247558","article-title":"Andexanet Alfa neutralizes the anticoagulant effects of unfractionated heparin of bovine, ovine and porcine origin almost as protamine sulfate","volume":"30","author":"Siddiqui","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib139","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1213\/ANE.0b013e3181e9ed15","article-title":"The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations","volume":"111","author":"Bolliger","year":"2010","journal-title":"Anesth Analg"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib140","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2009-05-222109","article-title":"Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation","volume":"114","author":"Ni Ainle","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib141","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib142","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH07-05-0357","article-title":"Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro","volume":"100","author":"Gatt","year":"2008","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib143","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1160\/TH03-07-0483","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"Gerotziafas","year":"2004","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib144","first-page":"251","article-title":"Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial","volume":"116","author":"Meesters","year":"2016","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib145","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/jth.14470","article-title":"Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application","volume":"17","author":"Douxfils","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib146","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.thromres.2006.05.008","article-title":"Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro","volume":"119","author":"Lau","year":"2007","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib147","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ijlh.13703","article-title":"Study of in vitro thrombin generation after neutralization of heparin","volume":"44","author":"Hardy","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib148","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/abio.1999.4380","article-title":"The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation","volume":"277","author":"Ramjee","year":"2000","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib149","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ijlh.13735","article-title":"The modification of the thrombin generation assay for the clinical assessment of hypercoagulability in patients receiving heparin therapy","volume":"44","author":"Benoit","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1213\/ANE.0000000000001098","article-title":"Optimizing thrombin generation with 4-factor prothrombin complex concentrates in neonatal plasma after cardiopulmonary bypass","volume":"122","author":"Franklin","year":"2016","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MBC.0000000000000379","article-title":"Changes in thrombin generation in children after cardiac surgery and ex-vivo response to blood products and haemostatic agents","volume":"27","author":"Andreasen","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib152","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MBC.0000000000000243","article-title":"Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass","volume":"26","author":"Percy","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib153","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/bja\/aet355","article-title":"Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass","volume":"112","author":"Guzzetta","year":"2014","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib154","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1213\/ane.0b013e318163fc76","article-title":"Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P)","volume":"106","author":"Tanaka","year":"2008","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib155","first-page":"1","article-title":"Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential)","volume":"26","author":"Rotteveel","year":"1996","journal-title":"Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib156","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1053\/j.jvca.2019.12.008","article-title":"Thrombin generation and antithrombin activity in infants undergoing cardiopulmonary bypass-an exploratory study","volume":"34","author":"Ashikhmina","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.pharmr.2026.100135_bib157","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2017.09.021","article-title":"Calibrated automated thrombogram values in infants with cardiac surgery before and after cardiopulmonary bypass","volume":"160","author":"Rizza","year":"2017","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib158","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.thromres.2013.12.017","article-title":"Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery","volume":"133","author":"Bosch","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2026.100135_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221144042","article-title":"Does intraoperative fibrinogen affect blood loss or transfusion practice after aortic arch surgery: a prematurely ended randomized trial","volume":"28","author":"Vlot","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.thromres.2011.12.025","article-title":"Sustained heparin effect contributes to reduced plasma thrombin generation capacity early after cardiac surgery","volume":"130","author":"Radulovic","year":"2012","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib161","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1051\/ject\/201143019","article-title":"Thrombography reveals thrombin generation potential continues to deteriorate following cardiopulmonary bypass surgery despite adequate hemostasis","volume":"43","author":"Wong","year":"2011","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib162","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2011.02.022","article-title":"Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery","volume":"128","author":"Solomon","year":"2011","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib163","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00246-011-9929-4","article-title":"Hemostatic response in paediatric patients undergoing cardiopulmonary bypass surgery","volume":"32","author":"Ignjatovic","year":"2011","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib164","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1160\/TH09-06-0396","article-title":"Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery","volume":"103","author":"Schols","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib165","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221123310","article-title":"Assessment of rotational thromboelastometry and thrombin generation assay to identify risk of high blood loss and re-operation after cardiac surgery","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib166","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1213\/ANE.0000000000005840","article-title":"Thrombin generation in cardiac versus noncardiac surgical cohorts","volume":"134","author":"Ericksen","year":"2022","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib167","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12630-021-02165-1","article-title":"The association of thrombin generation with bleeding outcomes in cardiac surgery: a prospective observational study","volume":"69","author":"Bartoszko","year":"2022","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.pharmr.2026.100135_bib168","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2017.01.006","article-title":"Global impairments in the haemostasis systems after cardiopulmonary bypass","volume":"151","author":"He","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib169","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MBC.0000000000000980","article-title":"Fibrin clot susceptibility to lysis is impaired after on-pump coronary artery by-pass grafting with tranexamic acid: clinical implications","volume":"32","author":"Mazur","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MBC.0000000000000892","article-title":"Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis","volume":"31","author":"Batt","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128634","article-title":"Where and when to inject low molecular weight heparin in hemodiafiltration? A cross over randomised trial","volume":"10","author":"Dhondt","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib172","doi-asserted-by":"crossref","DOI":"10.1186\/cc8191","article-title":"Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates","volume":"13","author":"Oudemans-van Straaten","year":"2009","journal-title":"Crit Care"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100135_bib173","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1538-7836.2009.03514.x","article-title":"Thrombin generation and heparin-induced thrombocytopenia","volume":"7","author":"Tardy-Poncet","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib174","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1160\/TH12-05-0321","article-title":"Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia","volume":"109","author":"Tardy-Poncet","year":"2013","journal-title":"Thromb Haemost"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100135_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911219","article-title":"Anticoagulation monitoring with activated partial thromboplastin time and anti-Xa activity in Intensive Care Unit patients: interest of thrombin generation assay","volume":"23","author":"Billoir","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib176","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11239-010-0490-4","article-title":"Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles","volume":"30","author":"Ben-Hadj-Khalifa-Kechiche","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib177","first-page":"301","article-title":"Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins","volume":"29","author":"Nguy\u00ean","year":"1999","journal-title":"Haemostasis"},{"key":"10.1016\/j.pharmr.2026.100135_bib178","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijcard.2016.06.247","article-title":"Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes","volume":"220","author":"Laine","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib179","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1538-7836.2010.04162.x","article-title":"Thrombin generation in patients with a first acute myocardial infarction","volume":"9","author":"Smid","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib180","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2011.03.011","article-title":"Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?","volume":"128","author":"Skeppholm","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2026.100135_bib181","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.talanta.2017.12.055","article-title":"Thrombodynamics, a new global coagulation test: measurement of heparin efficiency","volume":"180","author":"Sinauridze","year":"2018","journal-title":"Talanta"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100135_bib182","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","article-title":"The purification and mechanism of action of human antithrombin-heparin cofactor","volume":"248","author":"Rosenberg","year":"1973","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100135_bib183","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/S0021-9258(19)70431-1","article-title":"The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin","volume":"255","author":"Jordan","year":"1980","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib184","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0021-9258(18)53998-3","article-title":"Complex-dependent inhibition of factor VIIa by antithrombin III and heparin","volume":"268","author":"Lawson","year":"1993","journal-title":"J Biol Chem"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100135_bib185","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1021\/bi0342923","article-title":"Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa","volume":"42","author":"Sheehan","year":"2003","journal-title":"Biochemistry"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100135_bib186","doi-asserted-by":"crossref","first-page":"26796","DOI":"10.1016\/S0021-9258(18)47089-5","article-title":"Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator","volume":"269","author":"Barrow","year":"1994","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib187","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.13679","article-title":"Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients","volume":"25","author":"Chelle","year":"2019","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100135_bib188","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib189","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2516.2005.01107.x","article-title":"Thrombin generation and phenotypic correlation in haemophilia A","volume":"11","author":"Beltr\u00e1n-Miranda","year":"2005","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib190","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0037-1613946","article-title":"Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro","volume":"83","author":"Hansen","year":"2000","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100135_bib191","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/01.ATV.19.9.2251","article-title":"Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture","volume":"19","author":"Lupu","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib192","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib193","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0049-3848(88)90340-4","article-title":"Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)","volume":"50","author":"Sandset","year":"1988","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2026.100135_bib194","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0049-3848(91)90402-I","article-title":"Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation","volume":"14","author":"Lindahl","year":"1991","journal-title":"Thromb Res Suppl"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0028-1086077","article-title":"Overview of direct thrombin inhibitors in clinical practice","volume":"34","author":"Bounameuax","year":"2008","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib196","first-page":"155","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100135_bib197","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2008.03162.x","article-title":"Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase","volume":"6","author":"M\u00fcller","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100135_bib198","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/01.ATV.0000228844.65168.d1","article-title":"Thrombin-cofactor interactions: structural insights into regulatory mechanisms","volume":"26","author":"Adams","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100135_bib199","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910803","article-title":"Exosite binding in thrombin: a global structural\/dynamic overview of complexes with aptamers and other ligands","volume":"22","author":"Troisi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100135_bib200","doi-asserted-by":"crossref","first-page":"18569","DOI":"10.1074\/jbc.M600752200","article-title":"The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII","volume":"281","author":"Bukys","year":"2006","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib201","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1538-7836.2010.03822.x","article-title":"The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin","volume":"8","author":"Wagenvoord","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmr.2026.100135_bib202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib203","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1538-7836.2003.00127.x","article-title":"Predicting the pharmacology of thrombin inhibitors","volume":"1","author":"Adams","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib204","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jtha.2025.01.008","article-title":"Andexanet-induced heparin resistance in cardiac surgery-a rapid review of case reports and series","volume":"23","author":"Mishima","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103191","article-title":"Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin","volume":"9","author":"van Haaps","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100135_bib206","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet Alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib207","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"issue":"1 Pt B","key":"10.1016\/j.pharmr.2026.100135_bib208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcin.2014.10.003","article-title":"Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb\/IIIa inhibitors in patients with acute coronary syndrome","volume":"8","author":"Navarese","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100135_bib209","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib210","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of Rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100135_bib211","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1016\/j.jtha.2025.08.003","article-title":"Direct oral anticoagulant (DOAC) levels, bleeding, and breakthrough thrombosis: fog of war","volume":"23","author":"Shaw","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2026.100135_bib213","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/j.thromres.2017.12.019","article-title":"Management of recurrent venous thromboembolism in patients with cancer: a review","volume":"164","author":"Piran","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2026.100135_bib214","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2020.01.010","article-title":"Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients","volume":"187","author":"van Es","year":"2020","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib215","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100135_bib216","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib217","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100135_bib218","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.jtha.2023.06.036","article-title":"Warfarin faring better: vitamin K antagonists beat Rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials","volume":"21","author":"Eikelboom","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100135_bib219","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","article-title":"Systematic review and meta-analysis of the efficacy and safety of apixaban compared to Rivaroxaban in acute VTE in the real world","volume":"3","author":"Aryal","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharmr.2026.100135_bib220","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijcard.2018.06.114","article-title":"A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants","volume":"269","author":"Cohen","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100135_bib221","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib222","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtha.2024.12.032","article-title":"Peak and trough concentrations of apixaban and Rivaroxaban in adult patients: a systematic review and meta-analysis","volume":"23","author":"Almalbis","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100135_bib223","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"issue":"10366","key":"10.1016\/j.pharmr.2026.100135_bib224","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100135_bib225","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","article-title":"Bivalirudin vs heparin anticoagulation in STEMI: confirmation of the BRIGHT-4 results","volume":"84","author":"Stone","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100135_bib226","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100135_bib227","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib228","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2026.100135_bib229","doi-asserted-by":"crossref","first-page":"e08","DOI":"10.15420\/ecr.2024.61","article-title":"Factor XI and atrial fibrillation: a mismatched pairing?","volume":"20","author":"Rocca","year":"2025","journal-title":"Eur Cardiol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100135_bib230","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100135_bib231","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral Rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100135_bib232","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"23_suppl 1","key":"10.1016\/j.pharmr.2026.100135_bib233","first-page":"I17","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100135_bib234","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100135_bib235","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100135_bib236","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib237","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis","volume":"6","author":"Fujisaki","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib238","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100135_bib239","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1055\/a-2521-0923","article-title":"Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: a nested case-control study","volume":"125","author":"Shaw","year":"2025","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100135_bib240","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1373\/clinchem.2008.112243","article-title":"Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer","volume":"54","author":"Eichinger","year":"2008","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100135_bib241","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3324\/haematol.2019.221655","article-title":"Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study","volume":"105","author":"van Paridon","year":"2020","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100135_bib242","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100135_bib243","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100135_bib244","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12654","article-title":"Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: assessment of analytical and between-subject variation","volume":"6","author":"Kristensen","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100135_bib245","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ijlh.13618","article-title":"Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants","volume":"43","author":"Metze","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pharmr.2026.100135_bib246","series-title":"Evaluating Evidence of Mechanisms in Medicine: Principles and Procedures","author":"Parkkinen","year":"2018"},{"key":"10.1016\/j.pharmr.2026.100135_bib247","series-title":"Mechanistic Evidence in Evidence-Based Medicine: A Conceptual Framework","author":"Goodman","year":"2013"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:47:19Z","timestamp":1779446839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":247,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0031699726000232"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100135","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation and the pharmacodynamics of parenteral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100135"}}